Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Flex | GitLab | Tempus AI | |
|---|---|---|---|
| Moat rating | none The FY2026 10-K (fiscal year ended March 31, 2026) concedes the core business is contested on every side: "Our industry is extremely competitive, many of our competitors have achieved substantial market share, and some may have lower cost structures or greater design, manufacturing, financial or other resources than we do." Customers "could in the future decide to in-source, dual-source, regionalize, or otherwise reallocate manufacturing volumes among suppliers", certain contracts "permit the customer to terminate the agreement for convenience upon prior written notice", and hyperscale customers "typically have substantial purchasing power and negotiating leverage". TradingPilot's stored fundamentals (SEC XBRL) show gross profit of $1,976 million on net sales of $28,502 million in fiscal 2023 and $2,567 million on $27,914 million in fiscal 2026: a thin margin, even after widening. The Cloud and Power Infrastructure (CPI) segment sells its own power and cooling products, but the 10-K says it must keep offering "significant price and/or performance advantages over competitive products", and Flex intends to separate it into an independent company targeted for the first quarter of calendar 2027. A large contract manufacturer whose own filing describes no protected position: no moat is claimable. | narrow The FY2026 10-K (year ended 2026-01-31) shows real expansion inside the installed base: 118% Dollar-Based Net Retention, Base Customers up to 10,682 from 9,893, customers above $100,000 of ARR up to 1,456 from 1,229, and $1.0 million ARR customers "to 155 from 123, an increase of 26%". But the filing concedes "limited barriers to entry" and names "Microsoft Corporation, which owns GitHub" as principal competitor. Retention decelerates (130% FY2024, 123% FY2025, 118% FY2026), and since DBNR is reported "on a threshold basis of 130%," the FY2024 figure is a cap and the slide is steeper than it looks. Narrow, not wide: expansion must be re-won against a bundled hyperscaler. | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." |
| Moat type | none The 10-K's competitive strengths are operating capabilities, not a durable barrier: "Global Scale and Regional Strength" (more than 100 facilities across approximately 30 countries, staffed by approximately 150,000 employees), "Long-Standing, Diverse Customer Relationships", "Cross-Industry Synergies" and cost-efficient industrial parks. On intellectual property it says "we do not consider any single patent, trademark, or license to be material to our business as a whole" and that the carrying value of its intellectual property "was not material". Switching costs are limited by short commitments: "We generally do not obtain firm, long-term purchase commitments from our customers", and termination-for-convenience notice periods "may be relatively short". | switching costs Stickiness comes from platform embedding, not IP. The 10-K rests differentiation on "our single platform with a unified data model," on "Consolidation of multiple tools into a single platform," and on deployment inside the customer's own perimeter for regulated buyers. Replacement means re-integrating a toolchain and re-certifying compliance. IP is the wrong label: only "16 issued patents and 25 pending patent applications," plus open-source licenses granting "broad permissions to use, copy, modify, and redistribute." The no-lock-in claim is the filing's own characterisation, footnoted to a Forrester study "commissioned by GitLab." | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. |
| Leadership | at parity EMSNOW/in4ma's "EMS&ODM Global 100" (2026-03-06, https://www.emsnow.com/?p=53535) says Wistron, Quanta and Wiwynn "plus Foxconn together account for nearly 57% of global EMS/ODM production", and groups Flex with Jabil, Celestica and Sanmina as the US "big four", "representing about 85% of the revenue base among ~20 US headquartered EMS/ODM". The FY2026 10-K claims no rank and says "many of our competitors have achieved substantial market share". One of a handful of large Western contract manufacturers, behind the Taiwanese leaders in scale: at parity with its peer group, not a leader. | fast follower The 10-K positions GitLab against a leader rather than as one: "Our principal competitor is Microsoft Corporation, which owns GitHub." Competition reads from the challenger side, differentiating "from GitHub through flexible deployment options that work within enterprise security and compliance requirements, LLM neutrality with self-hosted gateway support" and an open core model. On AI it follows: Duo Agent Platform went "Generally available in January 2026," the last month of the fiscal year. What keeps it a follower rather than behind is cadence, "a new version of our software every month for 172 months in a row," plus a regulated-deployment franchise a SaaS-first rival does not cover. | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. |
| Pricing power | weak Stored fundamentals show gross profit of $1,976 million on $28,502 million of net sales in fiscal 2023 and $2,567 million on $27,914 million in fiscal 2026; on the Q1 FY2027 call (https://earningswhispers.com/transcript/FLEX/Q12027) the CFO said adjusted gross margin "improved to 9.6%, up 50 basis points from the prior year". The 10-K sets the limits: hyperscale customers have "substantial purchasing power and negotiating leverage, which they may use to obtain favorable pricing, extended payment terms, volume flexibility, or other concessions that could reduce our margins", and if CPI's competitors "adopt innovations more quickly or develop superior products, our win rates, pricing, and margins may suffer". | moderate FY2026 gross margin was 87% against 89%, with cost of revenue up $35.6 million "primarily due to an increase of $18.4 million in third party hosting costs for SaaS and cloud usage," and management expects SaaS and Duo mix to bring costs that "may adversely impact our gross margins." Strain is explicit: GitLab "may be required to reduce our prices," competitors "may offer their products and services at a lower price or for free," and it "implemented user limits on our free SaaS product." Power retained: Premium lists at $29 per user/month billed annually, and seats bundle $12 and $24 of GitLab Credits. But "A majority of our subscriptions are on a one-year period." | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). |
| Summary | Flex designs, builds and manages products for other companies through, per its FY2026 10-K, three segments: Integrated Technology Solutions (communications, enterprise and lifestyle products), Regulated Manufacturing Solutions (industrial, automotive and healthcare) and Cloud and Power Infrastructure (integrated compute systems, liquid cooling, and utility-, facility-, rack- and board-level power). It runs more than 100 facilities in approximately 30 countries; its ten largest customers were 45% of fiscal 2026 net sales and none exceeded 10%. The data-centre business is the growth engine: on the Q1 FY2027 call (2026-07-29) the CFO said CPI revenue "totaled $2.2 billion, up 35% from the prior year, driven by strong growth in power", at a 9.7% adjusted operating margin, against 5.2% for ITS and 6.6% for RMS. Flex plans to spin CPI off as Axiom in the first quarter of calendar 2027, after funds affiliated with General Catalyst, Koch Equity Development and co-investors agreed a $2.0 billion convertible preferred investment "at an initial enterprise value for Axiom of $37.5 billion" (Flex release, 2026-10-05: https://www.sec.gov/Archives/edgar/data/866374/000119312526413173/d123485dex991.htm). The filing itself describes no durable barrier: the industry is "extremely competitive", rivals including Taiwanese ODM suppliers "in some cases, have a substantial share of global information technology hardware and related infrastructure production", customers can in-source or reallocate volume, and hyperscalers can use their leverage "to obtain favorable pricing". An independent tally (EMSNOW/in4ma, 2026-03-06) puts Foxconn, Wistron, Quanta and Wiwynn at "nearly 57% of global EMS/ODM production" and counts Flex among the US "big four". Scale plus a fast-growing power franchise that is about to leave the group, but no moat. | GitLab sells a single-platform DevSecOps toolchain defended by workflow lock-in rather than intellectual property: a unified data model plus deployment flexibility, including single-tenant "Dedicated for Government with FedRAMP compliance," makes it hard to remove where data residency is contractual. The installed base expands: 118% Dollar-Based Net Retention, 10,682 Base Customers, 1,456 above $100,000 of ARR, 155 above $1.0 million (up 26%), over 70% of ARR from public sector and enterprise. The filing supplies the counterweight: "limited barriers to entry," Microsoft/GitHub as principal competitor, 16 issued patents. Retention (130 to 123 to 118, the 130 a cap), gross margin (89% to 87%) and a January 2026 AI launch point to compression at the commodity end. No source measures market share, so every share band is "unknown". | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. |
| Chain position | Contract designer-manufacturer across many end markets and, through CPI, a supplier of power, cooling and rack-level compute infrastructure to "a limited number of hyperscale cloud providers, colocation companies, and large enterprise data center operators" (10-K), which Flex plans to separate as Axiom in the first quarter of calendar 2027. | GitLab sits at the software-tooling layer, not compute or models. It consumes third-party LLM capacity — marketing "LLM neutrality and support for self-hosted AI gateways, including air-gapped environments" — so it captures no model-layer economics and bears inference as COGS, visible in the $18.4 million rise in hosting costs. Its distinctive position is the regulated perimeter. | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. |